Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Adamis Pharmaceuticals Corp. (NASDAQ: ADMP).

Full DD Report for ADMP

You must become a subscriber to view this report.


Recent News from (NASDAQ: ADMP)

Adamis Pharmaceuticals: Paging Dr. Carlo
On May 10th, Adamis Pharmaceuticals ( ADMP ) delivered its latest corporate update along with its Q1 2018 earnings report . The welcome decision to include a corporate update continues a trend that began with the Q4 2017 earnings release. Previously, the company only disclosed the bare minimu...
Source: SeekingAlpha
Date: May, 14 2018 17:01
Adamis Pharmaceuticals misses on revenue
Adamis Pharmaceuticals (NASDAQ: ADMP ): Q1 Net loss of $7.6M Revenue of $3.2M (+5.3% Y/Y) misses by $0.38M . Shares -1.83% AH. Press Release More news on: Adamis Pharmaceuticals Corp., Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: May, 10 2018 18:00
Adamis Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update
SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced financial results and a business update for the first quarter ended March 31, 2018. Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals, said, &...
Source: GlobeNewswire
Date: May, 10 2018 17:51
Adamis Keeps Us Waiting: April Update
We have been writing about Adamis Pharmaceuticals ( ADMP ) for several months. We have opined on the value of its FDA-approved epinephrine injector, Symjepi, as well as that of its budding pipeline. We have also discussed at length the agonizingly long process the company has undertaken to fin...
Source: SeekingAlpha
Date: April, 28 2018 06:36
Recent Analysis Shows J.Jill, BankUnited, Toronto Dominion Bank, Adamis Pharmaceuticals, BioDelivery Sciences International, and First Solar Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of J.Jill, Inc. (NYSE:JILL), BankUnited, Inc. (NYSE:BKU), Toronto Dominion ...
Source: GlobeNewswire
Date: April, 19 2018 08:25
Adamis: Wait For It
Adamis Pharmaceuticals (ADMP) is burning cash fast, and they will continue to burn cash until they find a partner for Symjepi. Cash and dilution are now real concerns as there is not a timetable for a partnership deal. Time is not on ADMP´s side. The longer it takes to find a partner, t...
Source: SeekingAlpha
Date: April, 04 2018 12:00
Understanding Binary Catalysts: A Brief Guide For Biotech Investors
This article was co-authored by Stepan Lavrouk. Stepan is an investment analyst with Almington Capital. We have written extensively on Seeking Alpha about a range of biotech stocks. But we have also spent some time addressing the activity of biotech investing itself. In previous articles...
Source: SeekingAlpha
Date: March, 29 2018 02:38
Adamis Pharmaceuticals: The Latest Update Still Keeps Us Waiting
Investors in Adamis Pharmaceuticals ( ADMP ) are no strangers to long silences. Company management, under the leadership of CEO Dennis Carlo, has long made a habit of keeping mum about developments. This has been especially galling in recent months, as Adamis blew past its initial plans to sec...
Source: SeekingAlpha
Date: March, 21 2018 15:31
Your Daily Pharma Scoop: Aratana Earnings, Vanda Offering, Opko 4kscore Shows Benefit
Quick investment opinion: Aratana Therapeutics Aratana (NASDAQ: PETX ), which we covered in the early days of our Seeking Alpha work, released earnings this week. In our July 2017 article, we had said that although PETX is having trouble delivering drugs even after approval, its strong pip...
Source: SeekingAlpha
Date: March, 17 2018 08:00
Adamis Pharmaceuticals misses by $0.09, misses on revenue
Adamis Pharmaceuticals (NASDAQ: ADMP ): FY EPS of -$0.90 misses by $0.09 . Revenue of $13.07M (+102.0% Y/Y) misses by $1.33M . Press Release More news on: Adamis Pharmaceuticals Corp., Earnings news and commentary, Healthcare stocks news, ,
Source: SeekingAlpha
Date: March, 16 2018 10:06

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-202.502.3252.532.301,330,244
2018-08-172.852.402.902.352,960,710
2018-08-163.402.8253.502.802,471,403
2018-08-153.353.4253.453.30242,392
2018-08-143.453.353.4753.35271,331

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-20210,164648,42732.4114Cover
2018-08-17376,7241,036,42136.3485Short
2018-08-16214,071847,67525.2539Cover
2018-08-1523,42084,96327.5649Cover
2018-08-1427,94886,03032.4863Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ADMP.


About Adamis Pharmaceuticals Corp. (NASDAQ: ADMP)

Logo for Adamis Pharmaceuticals Corp. (NASDAQ: ADMP)

Adamis Pharmaceuticals Corporation is a publicly traded OTC: ADMP biopharmaceutical company combining specialty pharmaceuticals and biotechnology products to create a variety of treatment options in the areas of oncology cancer , immunology, infectious diseases viruses , as well as allergic and respiratory conditions. Adamis is built on a business model that entails licensing innovative programs from companies or institutions and then advancing these initiatives through clinical development, regulatory approvals, and marketing. In order to efficiently accomplish its objectives, the Company operates through two subsidiaries Adamis Laboratories specialty pharmaceuticals and Adamis Therapeutics biotechnology . This structure permits each division to complement one other by providing a combination of pharmaceutical revenue and biotechnology blockbuster potential. The specialty pharmaceutical division will provide revenue to support the development of the Company s therapeutic products.

 

Contact Information

 

 

Current Management

  • Dennis J. Carlo / President, CEO
  • Robert O. Hopkins / CFO
  • David J. Marguglio / SVP, Corp. Dev.
  • Dennis J. Carlo /
  • Kenneth M. Cohen /
  • Craig Johnson /
  • David J. Marguglio /
  • Tina S. Nova /

Current Share Structure

  • Market Cap: $126,879,758 - 05/14/2018
  • Issue and Outstanding: 33,389,410 - 03/15/2018

 


Recent Filings from (NASDAQ: ADMP)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: April, 30 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 27 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: February, 14 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: February, 14 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: February, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 05 2018

 

 


Daily Technical Chart for (NASDAQ: ADMP)

Daily Technical Chart for (NASDAQ: ADMP)


Stay tuned for daily updates and more on (NASDAQ: ADMP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ADMP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ADMP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ADMP and does not buy, sell, or trade any shares of ADMP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/